Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)
NCT03271021 is registered in ClinicalTrials.gov with Vyne Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)
- Lead sponsor
- Vyne Therapeutics Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 17, 2017
- Completion date
- September 4, 2018
- Enrollment
- 1,488 (actual)
- Sites
- 98
Conditions
As the registry lists them; a condition with its own page is linked.